Promising combo for resistant colon cancer never gets off the ground
NCT ID NCT06603818
First seen Feb 20, 2026 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This phase II study aimed to test two immunotherapy drugs (tiragolumab and atezolizumab) combined with targeted radiation in people with microsatellite stable (MSS) metastatic colorectal cancer, a type that typically doesn't respond to immunotherapy. The trial was withdrawn before enrolling any participants, so no data were collected. The goal was to find a safe dose and see if the combination could slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tiragolumab and atezolizumab (immunotherapy drugs) plus stereotactic body radiation therapy
What this could lead to
If it worked, this combination could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that doesn't respond to standard immunotherapy.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. Immunotherapies can cause immune-related side effects, and it's unknown if this combination would be effective in MSS colorectal cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.